Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Basit Öğe Kaydı
dc.authoridAykan, Nuri Faruk/0000-0002-5472-3218
dc.authoridyalcin, suayib/0000-0001-7850-6798
dc.authoridOzet, Ahmet/0000-0001-8731-9636
dc.authorwosidAykan, Nuri Faruk/I-6425-2019
dc.authorwosidyalcin, suayib/I-9035-2013
dc.contributor.authorOzet, Ahmet
dc.contributor.authorDane, Faysal
dc.contributor.authorAykan, Nuri Faruk
dc.contributor.authorYalcin, Suayib
dc.contributor.authorEvrensel, Turkkan
dc.contributor.authorOzkan, Metin
dc.contributor.authorKarabulut, Bulent
dc.date.accessioned2024-06-12T11:08:25Z
dc.date.available2024-06-12T11:08:25Z
dc.date.issued2022
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.en_US
dc.description.sponsorshipServieren_US
dc.description.sponsorshipThis study was sponsored by Servier..I Cic in: consulting/advisory for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, Roche, Quintiles; research funding for Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Merck, Merck Serono, Parexel, Pfizer, Quintiles, Taiho; there are no other conflicts of interest. MN Ormeci, O Atasev and L Vidot: employees of Servier. SYalc in: consulting/advisory for Eli Lilly, Merck, Amgen, Novartis, Pfizer, Gen. Ilac, Eczacibas i, Roche, Pierre Fabre, Polifarma, Astellas, Abbott, MSD, I.lko. A Ozet: received research funding for this study from Servier. NF Aykan, F Dane, T Evrensel, M Ozkan and B Karabulut: no conflicts of interest to report. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subjectmatter ormaterials discussed in the manuscript apart from those disclosed. M Gilmour and E Meredith of Empowering Strategic Performance (ESP) Ltd, Crowthorne, UK, provided medical writing support, which was sponsored by Servier, in accordance with Good Publication Practice guidelines.en_US
dc.identifier.doi10.2217/fon-2022-0455
dc.identifier.endpage3276en_US
dc.identifier.issn1479-6694
dc.identifier.issn1744-8301
dc.identifier.issue29en_US
dc.identifier.pmid36040321en_US
dc.identifier.scopus2-s2.0-85140272327en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3267en_US
dc.identifier.urihttps://doi.org/10.2217/fon-2022-0455
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22423
dc.identifier.volume18en_US
dc.identifier.wosWOS:000847506600001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofFuture Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMetastatic Colorectal Canceren_US
dc.subjectPRECONNECT Studyen_US
dc.subjectReal-World Dataen_US
dc.subjectTrifluridine/Tipiracilen_US
dc.subjectTurkish Populationen_US
dc.subjectNeutropeniaen_US
dc.subjectSurvivalen_US
dc.titleSafety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu